全文获取类型
收费全文 | 206篇 |
免费 | 11篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 3篇 |
妇产科学 | 5篇 |
基础医学 | 22篇 |
口腔科学 | 4篇 |
临床医学 | 15篇 |
内科学 | 47篇 |
皮肤病学 | 7篇 |
神经病学 | 10篇 |
特种医学 | 1篇 |
外科学 | 67篇 |
综合类 | 2篇 |
一般理论 | 1篇 |
预防医学 | 4篇 |
眼科学 | 2篇 |
药学 | 9篇 |
肿瘤学 | 17篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 18篇 |
2020年 | 4篇 |
2019年 | 14篇 |
2018年 | 13篇 |
2017年 | 5篇 |
2016年 | 10篇 |
2015年 | 11篇 |
2014年 | 20篇 |
2013年 | 11篇 |
2012年 | 24篇 |
2011年 | 13篇 |
2010年 | 10篇 |
2009年 | 12篇 |
2008年 | 15篇 |
2007年 | 7篇 |
2006年 | 4篇 |
2005年 | 3篇 |
2004年 | 2篇 |
2003年 | 3篇 |
2002年 | 5篇 |
1999年 | 1篇 |
1998年 | 2篇 |
1992年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有218条查询结果,搜索用时 0 毫秒
71.
Using proteins in a therapeutic context often requires engineering to modify functionality and enhance efficacy. We have previously reported that the therapeutic antileukemic protein macromolecule Escherichia coli L-asparaginase is degraded by leukemic lysosomal cysteine proteases. In the present study, we successfully engineered L-asparaginase to resist proteolytic cleavage and at the same time improve activity. We employed a novel combination of mutant sampling using a genetic algorithm in tandem with flexibility studies using molecular dynamics to investigate the impact of lid-loop and mutations on drug activity. Applying these methods, we successfully predicted the more active L-asparaginase mutants N24T and N24A. For the latter, a unique hydrogen bond network contributes to higher activity. Furthermore, interface mutations controlling secondary glutaminase activity demonstrated the importance of this enzymatic activity for drug cytotoxicity. All selected mutants were expressed, purified, and tested for activity and for their ability to form the active tetrameric form. By introducing the N24A and N24A R195S mutations to the drug L-asparaginase, we are a step closer to individualized drug design. 相似文献
72.
73.
74.
75.
Stanescu HC Arcos-Burgos M Medlar A Bockenhauer D Kottgen A Dragomirescu L Voinescu C Patel N Pearce K Hubank M Stephens HA Laundy V Padmanabhan S Zawadzka A Hofstra JM Coenen MJ den Heijer M Kiemeney LA Bacq-Daian D Stengel B Powis SH Brenchley P Feehally J Rees AJ Debiec H Wetzels JF Ronco P Mathieson PW Kleta R 《The New England journal of medicine》2011,364(7):616-626
76.
The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid‐liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life‐threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review. 相似文献
77.
78.
79.
Naina HV Harris S 《The New England journal of medicine》2008,359(1):98; author reply 98-98; author reply 99
80.